Roche has provided a re-assuring update for its Diagnostics division. Besides leveraging the COVID-19 testing opportunity, the group is well-positioned to capitalise the pandemic-driven emphasis on testing and investment in healthcare infrastructure. These are soothing developments, especially at a time when the core Pharma division may take some quarters before witnessing a complete recovery/normalisation. Moreover, with the group recently resorting to inorganic growth in diagnostics, we believ ....
24 Mar 2021
Takeaways from 2021 ‘Diagnostics’ Investors Day
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Takeaways from 2021 ‘Diagnostics’ Investors Day
- Published:
24 Mar 2021 -
Author:
Amandeep Goyal -
Pages:
4
Roche has provided a re-assuring update for its Diagnostics division. Besides leveraging the COVID-19 testing opportunity, the group is well-positioned to capitalise the pandemic-driven emphasis on testing and investment in healthcare infrastructure. These are soothing developments, especially at a time when the core Pharma division may take some quarters before witnessing a complete recovery/normalisation. Moreover, with the group recently resorting to inorganic growth in diagnostics, we believ ....